{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:06:49Z","timestamp":1770836809740,"version":"3.50.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00846","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T09:28:23Z","timestamp":1564392503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Olanzapine-Induced Hyperprolactinemia: Two Case Reports"],"prefix":"10.3389","volume":"10","author":[{"given":"Pedro Cabral","family":"Barata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio Jo\u00e3o","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Carlos","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"key":"B1","article-title":"Switching or discontinuing psychotropics","volume-title":"Psychotropic drug directory","author":"Bazire","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine: pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.psychres.2010.10.020","article-title":"Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women","volume":"187","author":"Houston","year":"2011","journal-title":"Psychiatry Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.rpsm.2015.11.003","article-title":"Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia","volume":"9","author":"Montejo","year":"2016","journal-title":"Rev. Psiquiatr. Salud Ment."},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.yfrne.2017.02.003","article-title":"Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics","volume":"45","author":"Montejo","year":"2017","journal-title":"Front. Neuroendocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","article-title":"Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis","volume":"32","author":"P\u00e9rez-Iglesias","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/JCP.0000000000000142","article-title":"Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia","volume":"34","author":"Takeuchi","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"B9","first-page":"94","article-title":"Akathisia","volume-title":"The Maudsley Prescribing guidelines in psychiatry","author":"Taylor","year":"2018"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.2147\/NDT.S180303","article-title":"Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia","volume":"14","author":"Yang","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.pnpbp.2010.02.014","article-title":"Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia","volume":"34","author":"Yasui-Furukori","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00846\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T09:28:25Z","timestamp":1564392505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00846\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":11,"alternative-id":["10.3389\/fphar.2019.00846"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00846","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"article-number":"846"}}